Search
EHA Friends' Fund
Together, we can change the lives of many and make greater strides in the treatment of patients with blood disorders.
Read moreEHA supports the proposal for a Regulation on the European Health Data Space (EHDS)
On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.
Read moreNew EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect
On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro diagnostic medical devices.
Read moreNobel prize goes to immunotherapy researchers
October 1, Sweden - Cancer kills millions of people every year and is one of humanity’s greatest health challenges.
Read moreHARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers
HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses.
Read moreKiller antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read moreNovel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read more